Adrenal Diabetes Metabolism Obesity Cardiovascular Bone Endocrine-Disrupting Chemicals Endocrine-Related Cancer Neuroendocrinology Reproduction Steroid and Steroidogenesis Thyroid
AstraZeneca plan to move more trial data collection to participants’ homes in a bid to improve study recruitment and thereby increase diversity amongst volunteers.
Administration of progesterone to women at greater risk of miscarriage has just been approved by the National Institute for Health and Care Excellence in the UK.
According to a mouse study, published in Nature Communications, stress hormones are able to reduce our immune protection from harmful gut bacteria and can lead to inflammatory flare ups, such as Crohn’s disease.
A Dutch study, published in Diabetologia, reports that women who’s physical activity was 4 hours of standing plus 3 hours of walking per day had better insulin sensitivity than those undertaking 1 hour of moderate to vigorous exercise each day.
The European Medicines Agency has approved once-weekly administration of lonapegsomatropin (TransCon hGH, Ascendis Pharma) for 3-18 year olds to treat growth hormone deficiency.
According to a study published in Diabetic Medicine, around a third of adults living with diabetes experience sexual dysfunction, with women more likely to also suffer from anxiety and diabetes-related distress.
According to research, published in Medicine, cardiovascular disease is more common in patients suffering from follicular thyroid cancer with increased total cholesterol levels.
Research presented at the recent Society for Endocrinology annual conference in Edinburgh, suggests that an AstraZeneca drug that inhibits the enzyme 11β-hydroxysteroid dehydrogenase type 1 may improve wound healing in type 2 diabetes patients.
Dexamethasone effectively reduces COVID-19 deaths but potential diabetic-like complications should be monitored, according to a study presented at the recent Society for Endocrinology annual conference in Edinburgh.
A study published in The Journal of Clinical Endocrinology & Metabolism indicates that children may not need additional growth-promoting therapies if their congenital adrenal hyperplasia is well managed.
